Mumbai, India – Industry leaders from the MedTech and in-vitro diagnostics (IVD) sectors recently gathered at the o3 Capital Convergence panel discussion in Mumbai to explore the rapidly evolving diagnostics landscape and the opportunities shaping the future of healthcare.

The discussion focused on key industry themes including scalability, consolidation, technology adoption, integrated care delivery, and the growing need to build sustainable and profitable healthcare models capable of meeting rising healthcare demands.

Representing Erba Transasia, Mr. Nikhil Vazirani, Chief Technology Officer, shared insights on how Indian diagnostics and MedTech companies can strengthen their global competitiveness by leveraging strong domestic scale, deeper vertical integration, robust research and development capabilities, and adherence to international quality standards.

He also highlighted the increasing role of advanced technologies across Immunology, PCR, Genetics, and digitally enabled healthcare ecosystems, which are expected to drive the next phase of growth and innovation in the diagnostics industry.

The discussion underscored the significant transformation underway within the Indian diagnostics sector, with innovation, accessibility, technological advancement, and evolving patient needs creating new opportunities for growth and global leadership.

As healthcare systems continue to evolve, industry collaboration and continued investment in innovation will remain critical in building a resilient, future-ready diagnostics ecosystem.